transmembrane 4 L six family member 1Genealiases: H-L6 · L6 · M3S1 · TAAL6
Q-omics provides the consensus-scored TM4SF1 profile across patient tissues and cancer cell-line models. TM4SF1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TM4SF1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TM4SF1 RNA expression shows 17,064 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where TM4SF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM4SF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM4SF1 survival associations across molecular data types. TM4SF1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM4SF1 RNA expression–survival associations across cancer types. High TM4SF1 expression shows unfavorable associations in BLCA, UVM, LIHC, LUAD, LGG and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TM4SF1 RNA expression.
This table summarizes TM4SF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TM4SF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM4SF1 shows lower tumor expression in KICH, UCEC and BRCA and higher tumor expression in COAD, THCA and STAD. The COAD box plot shows higher TM4SF1 RNA expression in tumor versus normal tissue (log2 FC = +1.514, t-test p < 0.001).
This table shows molecular features associated with TM4SF1 in patient tissues and cancer cell lines. In patient samples, TM4SF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TM4SF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
